TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35509708

Group type: EXPERIMENTAL
Intervention: autograft + rhBMP-2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: absorbable collagen sponge + rhBMP-2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: β-tricalcium phosphate + rhBMP-2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: bovine xenograft + rhBMP-2
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: hydroxyapatite + rhBMP-2
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study: 32427115

Group type: EXPERIMENTAL
Intervention: Mobile app
Number of subjects: 53

Group type: COMPARATOR
Intervention: No mobile app
Number of subjects: 53
Study: 35609024

Group type: EXPERIMENTAL
Intervention: Amoxicillin 250mg capsule with ranitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin 250mg capsule without ranitidine
Number of subjects: 0
Study: 32303794

Group type: EXPERIMENTAL
Intervention: High individual lymphocytic subsets and sTIL density
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Higher sTIL density (10% increments)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Higher total CD3+ TILs
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Higher total CD8+ TILs
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Stromal and intratumoral CD3+, CD8+, and FOXP3+ TIL density
Number of subjects: 1011
Study: 35217280

Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid (30% in 95% DMSO), applied twice daily for 8 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical imiquimod, a standard topical treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid
Number of subjects: 25

Group type: COMPARATOR
Intervention: Topical imiquimod
Number of subjects: 25
Study: 34006020

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham transplantation (Control)
Number of subjects: 10
Study: 32562721

Group type: EXPERIMENTAL
Intervention: CADe colonoscopy
Number of subjects: 369

Group type: COMPARATOR
Intervention: Routine colonoscopy
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: CADe colonoscopy (ascending colon)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: CADe colonoscopy (transverse colon)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: CADe colonoscopy (descending colon)
Number of subjects: 369
Study: 34929354

Group type: EXPERIMENTAL
Intervention: TP-PDT (tri-needle-pretreatment with ALA-PDT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: NP-PDT (conventional ALA-PDT without pretreatment)
Number of subjects: 48
Study: 35835728

Group type: EXPERIMENTAL
Intervention: Goggles and snorkel (GS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No goggles and snorkel (NGS)
Number of subjects: 40
Study: 33879842

Group type: EXPERIMENTAL
Intervention: Hydromorphone + Dronabinol 2.5 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hydromorphone + Dronabinol 5 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hydromorphone + Dronabinol 10 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydromorphone only
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg, 5.0 mg, 10 mg)
Number of subjects: 29
Study: 32973113

Group type: EXPERIMENTAL
Intervention: Staged angioplasty (SAP)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Regular carotid artery stenting (CAS)
Number of subjects: 64
Study: 32027457

Group type: COMPARATOR
Intervention: Fostemsavir 1,200 mg b.i.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fostemsavir 2,400 mg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMR concentrations up to 7,500 ng/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fostemsavir 600 mg b.i.d. (in phase III BRIGHTE study)
Number of subjects: 0
Study: 35012798

Group type: EXPERIMENTAL
Intervention: Neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Number of subjects: 0
Study: 33760671

Group type: EXPERIMENTAL
Intervention: LED photobiomodulation (red 660 ± 20 nm, 5 mW/cm2, 3 J per LED, total energy=216 J) for 10 minutes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hot shower for 30 minutes
Number of subjects: 29
Study: 35782290

Group type: EXPERIMENTAL
Intervention: Online laughter therapy (10 sessions, 2 days a week for 5 weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study: 36455068

Group type: EXPERIMENTAL
Intervention: Pretomanid and rifampicin (Arm 1)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Pretomanid and rifabutin (Arm 2)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Rifampicin and ethambutol (standard of care, Arm 3)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 157
Study: 32567237

Group type: EXPERIMENTAL
Intervention: Eye patching with a single dose of local steroid and antibiotic for 24 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plastic shield with local steroid and antibiotic drops
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 32621741

Group type: EXPERIMENTAL
Intervention: 1 mOPV2 dose
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2 mOPV2 doses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 100
Study: 32569123

Group type: EXPERIMENTAL
Intervention: Assisted Nordic Hamstring Exercise (5-20% of body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unassisted Nordic Hamstring Exercise
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Assisted Nordic Hamstring Exercise
Number of subjects: 16
Study: 36396434

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase treatment (IVT) followed by endovascular treatment (EVT)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Endovascular treatment (EVT) alone
Number of subjects: 539
Study: 33398423

Group type: EXPERIMENTAL
Intervention: HP-HoLEP (80-100 W)
Number of subjects: 90

Group type: COMPARATOR
Intervention: MP-HoLEP (50-60 W)
Number of subjects: 90
Study: 35503379

Group type: EXPERIMENTAL
Intervention: Somatostatin analogues (SSAs) - octreotide acetate LAR every 4 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Best supportive care (Control)
Number of subjects: 115
Study: 34167594

Group type: EXPERIMENTAL
Intervention: Combination of conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg (Duavive)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34036796

Group type: EXPERIMENTAL
Intervention: Minipercutaneous nephrolithotomy under mixture of local anesthetics (MLA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spinal anesthesia (SA)
Number of subjects: 120
Study: 35262461

Group type: EXPERIMENTAL
Intervention: Virtual reality technology for intravenous catheterization training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intravenous injection arm model (control)
Number of subjects: 56
Study: 34324930

Group type: EXPERIMENTAL
Intervention: Preventive intercostal nerve block (INB) with ropivacaine before intrathoracic manipulation combined with patient-controlled analgesia (PCA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post-procedural intercostal nerve block (INB) with ropivacaine at the end of the operation combined with PCA
Number of subjects: 50
Study: 36415742

Group type: EXPERIMENTAL
Intervention: Modified Danggui-Shaoyao San (MDSS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 62
Study: 32899073

Group type: EXPERIMENTAL
Intervention: True acupoints treatment group (TATG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sham acupoints treatment group (SATG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 34320413

Group type: EXPERIMENTAL
Intervention: ChAdOx1-S (AZD1222) vaccine
Number of subjects: 1592
Study: 36056382

Group type: EXPERIMENTAL
Intervention: Jin-shui Huan-xian granule (JHG)
Number of subjects: 312

Group type: COMPARATOR
Intervention: JHG placebo
Number of subjects: 312
Study: 34874138

Group type: EXPERIMENTAL
Intervention: 67% Sodium Bicarbonate Toothpaste
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 62% Sodium Bicarbonate Toothpaste
Number of subjects: 330

Group type: COMPARATOR
Intervention: 0% Sodium Bicarbonate Toothpaste
Number of subjects: 330
Study: 35727711

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 400 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 1600 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 32564058

Group type: EXPERIMENTAL
Intervention: Conceived while on ART
Number of subjects: 826

Group type: COMPARATOR
Intervention: Restarted ART after pregnancy diagnosis
Number of subjects: 826
Study: 32097092

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 75 mg/m2 every 3 weeks × 4 doses
Number of subjects: 118

Group type: COMPARATOR
Intervention: Doxorubicin-Cyclophosphamide (AC) doxorubicin 60 mg/m2; cyclophosphamide 600 mg/m2 every 2-3 weeks × 4 doses
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Doxorubicin-Cyclophosphamide (AC)
Number of subjects: 118
Study: 34907536

Group type: EXPERIMENTAL
Intervention: Terumo BCT freeze-dried plasma (TFDP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent apheresis fresh-frozen plasma (CC-AFFP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled frozen plasma (FP)
Number of subjects: 0
Study: 32702664

Group type: EXPERIMENTAL
Intervention: Exergaming-based dance aerobic training for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (1-hr education on conventional physical exercises)
Number of subjects: 20
Study: 35332736

Group type: EXPERIMENTAL
Intervention: Oxytocin injection plus ergometrine injection
Number of subjects: 305

Group type: COMPARATOR
Intervention: Oxytocin injection
Number of subjects: 305
Study: 35698580

Group type: EXPERIMENTAL
Intervention: Masitinib (6 mg/kg/d)
Number of subjects: 355
Study: 33010183

Group type: EXPERIMENTAL
Intervention: Combined aerobic exercise with guided-mindfulness relaxation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerobic exercise only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Relaxation only
Number of subjects: 40
Study: 35801005

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg 2 hours before surgery, 40 mg/day after surgery, and 20 mg/day 1 week later
Number of subjects: 98

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg every night after admission (Control)
Number of subjects: 98
Study: 34871052

Group type: EXPERIMENTAL
Intervention: Progressive exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice advice with corticosteroid injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice advice without corticosteroid injection
Number of subjects: 0
Study: 35739556

Group type: EXPERIMENTAL
Intervention: Mind My Mind (MMM) transdiagnostic psychotherapy program
Number of subjects: 396
Study: 32909600

Group type: EXPERIMENTAL
Intervention: Physical fitness (measured by push-ups and total fitness points)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Physical fitness (measured by total fitness points)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Fitness total points and BMI
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Class means of fitness total points and BMI
Number of subjects: 192
Study: 33423878

Group type: EXPERIMENTAL
Intervention: Ultra-short cementless anatomic stem
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Conventional length cementless anatomic stem
Number of subjects: 1518
Study: 34413491

Group type: EXPERIMENTAL
Intervention: Air
Number of subjects: 262

Group type: COMPARATOR
Intervention: Gas
Number of subjects: 262
Study: 32330373

Group type: EXPERIMENTAL
Intervention: Verum test dietary supplement (TDS) containing l-carnitine/acetyl-l-carnitine, l-arginine, glutathione, co-enzyme Q10, zinc, vitamin B9, vitamin B12, selenium, taken 1 time daily for 6 months
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo, taken 1 time daily for 6 months
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Verum test dietary supplement (TDS)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 36001306

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg/70 kg for first session; 25-40 mg/70 kg for second session)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Diphenhydramine (50 mg for first session; 50-100 mg for second session)
Number of subjects: 95
Study: 33122574

Group type: EXPERIMENTAL
Intervention: Ultrasound assistance (preprocedural ultrasound scan, puncture site identified by ultrasound imaging)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ultrasound assistance
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional palpation (sham procedural ultrasound scan, puncture site identified by conventional palpation)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Conventional palpation
Number of subjects: 185
Study: 32243943

Group type: EXPERIMENTAL
Intervention: Hydrocortisone, vitamin C, and thiamine combination treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study: 35094028

Group type: EXPERIMENTAL
Intervention: Atropine 0.01% eyedrops
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 73
Study: 33401157

Group type: EXPERIMENTAL
Intervention: 5 fractions of whole-breast irradiation (5*5.7 Gy, total 28.5 Gy)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 15 fractions of whole-breast irradiation (15*2.67 Gy, total 40.05 Gy)
Number of subjects: 200
Study: 32481760

Group type: EXPERIMENTAL
Intervention: WHS 300 mg
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: WHS 600 mg
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 32939860

Group type: EXPERIMENTAL
Intervention: Brodalumab (210 mg subcutaneous injections)
Number of subjects: 210
Study: 32216032

Group type: EXPERIMENTAL
Intervention: 50 IU/kg Eprex (low-dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 IU/kg Eprex (micro-dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 24
Study: 32797324

Group type: COMPARATOR
Intervention: No-POCs group (C-D = 0)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: L-POCs group (C-D = I-II)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: M-POCs group (C-D = III, IV, or V)
Number of subjects: 3
Study: 34268283

Group type: EXPERIMENTAL
Intervention: Stepwise model based on predictors chosen by XGBoost
Number of subjects: 15928

Group type: EXPERIMENTAL
Intervention: External validation cohort of 11,113 Japanese participants
Number of subjects: 15928
Study: 34581507

Group type: EXPERIMENTAL
Intervention: Supervised home spirometry
Number of subjects: 61

Group type: COMPARATOR
Intervention: Unsupervised home spirometry
Number of subjects: 61
Study: 34430440

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (aspirin plus clopidogrel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin therapy alone (Control group)
Number of subjects: 0
Study: 35133989

Group type: EXPERIMENTAL
Intervention: Low-AGE diet
Number of subjects: 73

Group type: COMPARATOR
Intervention: High-AGE diet
Number of subjects: 73
Study: 32820475

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vasopressin, Angiotensin II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inotropic agents (e.g., dobutamine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selepressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine and Norepinephrine
Number of subjects: 0
Study: 33795322

Group type: EXPERIMENTAL
Intervention: ICS/LABA therapy for 12 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: LABA alone
Number of subjects: 63
Study: 33032652

Group type: EXPERIMENTAL
Intervention: SPAD value measured from T1 (top most leaf) and T3 (2nd leaf from top leaf) during vegetative phase.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SPAD value measured from eo (leaf attached to ear) and e2 (2nd leaf from eo leaf) during reproductive phase.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Correlation analysis of SPAD values with grain yield.
Number of subjects: 10
Study: 36526515

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 5795

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5795
Study: 32569082

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (6-week, 18-session)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual activity control
Number of subjects: 82
Study: 33065820

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Rhythm Group Therapy (CBSRT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Present Centered Therapy (PCT)
Number of subjects: 43
Study: 35288469

Group type: EXPERIMENTAL
Intervention: Nivolumab with cabozantinib (Arm A)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nivolumab alone (Arm B)
Number of subjects: 54
Study: 35790329

Group type: EXPERIMENTAL
Intervention: Social Participation-focused Virtual Reality (SP-VR) intervention, 6-week program with two sessions weekly.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual care (conventional physical therapy services)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: User satisfaction evaluation among both survivors and caregivers
Number of subjects: 250
Study: 33516651

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (stature, BMI) and nasopharyngeal dimensions (bony nasopharynx area)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (stature, BMI) and nasopharyngeal dimensions (bony and soft tissue variables)
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Lower facial height
Number of subjects: 483
Study: 32174079

Group type: EXPERIMENTAL
Intervention: 3D printing guide plate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional procedure
Number of subjects: 60
Study: 34791679

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks for 16 weeks) plus timothy grass (TG) SCIT
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dupilumab only
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: SCIT + dupilumab
Number of subjects: 52
Study: 35477159

Group type: EXPERIMENTAL
Intervention: Curcumin (HydroCurc®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 36380576

Group type: EXPERIMENTAL
Intervention: 2.5 h online training focusing on communication planning, self-efficacy, and communicating personal needs and preferences under difficult circumstances.
Number of subjects: 424

Group type: COMPARATOR
Intervention: Passive control group (no active intervention).
Number of subjects: 424
Study: 33439945

Group type: EXPERIMENTAL
Intervention: 50 IU/mL heparin solution
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.9% isotonic saline solution
Number of subjects: 17
Study: 32887653

Group type: EXPERIMENTAL
Intervention: Daily aspirin therapy (100 or 300 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35081255

Group type: EXPERIMENTAL
Intervention: Gilteritinib
Number of subjects: 371

Group type: COMPARATOR
Intervention: Salvage chemotherapy (SC)
Number of subjects: 371
Study: 33887548

Group type: EXPERIMENTAL
Intervention: Situational adaptation training combined with child-friendly nursing
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine operating room nursing
Number of subjects: 160
Study: 34090870

Group type: EXPERIMENTAL
Intervention: 20% Intralipid infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 19
Study: 34216212

Group type: COMPARATOR
Intervention: IPTp-SP
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: IPTp-DP
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Placental malaria exposure
Number of subjects: 387
Study: 35321125

Group type: EXPERIMENTAL
Intervention: Combined face‐to‐face and web‐based intervention
Number of subjects: 858

Group type: COMPARATOR
Intervention: Web‐based intervention
Number of subjects: 858

Group type: COMPARATOR
Intervention: Face‐to‐face intervention
Number of subjects: 858

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 858
Study: 35731086

Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: In-person rehabilitation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 34383972

Group type: EXPERIMENTAL
Intervention: PG‐SGA SF score ?15
Number of subjects: 2144
Study: 32111916

Group type: EXPERIMENTAL
Intervention: 0.375% ropivacaine (Ropivacaine group, 48 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (Control group, 52 patients)
Number of subjects: 100
Study: 36357639

Group type: EXPERIMENTAL
Intervention: Preemptive transplantation
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dialysis before transplantation
Number of subjects: 146
Study: 34703265

Group type: EXPERIMENTAL
Intervention: Setipiprant 1000 mg BID
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg
Number of subjects: 169
Study: 35502471

Group type: EXPERIMENTAL
Intervention: Watch group (first-generation Apple Watch + iPhone)
Number of subjects: 170

Group type: COMPARATOR
Intervention: iPhone group
Number of subjects: 170
Study: 34245918

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 8
Study: 35570397

Group type: EXPERIMENTAL
Intervention: 1565-nm non-ablative fractional laser (NAFL)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: topical β-glucan
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1565-nm NAFL combined with topical β-glucan (B + NAFL)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1565-nm NAFL combined with topical vehicle (NAFL)
Number of subjects: 64

Group type: COMPARATOR
Intervention: topical vehicle (Veh)
Number of subjects: 64